May 1st 2024
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors
July 1st 2020Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.
Watch
CD40 Agonist Plus Chemotherapy Hypothesized to Improve Outcomes in Metastatic PDAC
June 16th 2020In an interview with Targeted Oncology, Andrew L. Coveler, MD, discussed the phase 1 trial study of SEA-CD40 combined with a chemotherapy regimen, which he recently presented during the ASCO Virtual Scientific Program.
Read More
FDA Approves Nivolumab for Unresectable Esophageal Squamous Cell Carcinoma
June 11th 2020The FDA granted approval to nivolumab for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma after receiving prior fluoropyrimidine- and platinum-based chemotherapy.
Read More
FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan in HER2+ Gastric Cancer
May 11th 2020Trastuzumab deruxtecan received Breakthrough Therapy Designation for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.
Read More
Concepts for Targeting the Metastatic Process in Pancreatic Cancer
May 3rd 2020In an interview with Targeted Oncology, Gregory L. Beatty, MD, PhD, discussed the science behind the development of metastases in pancreatic tumors, including how metastases differ in various sites in the body. He also reviewed the treatment options for this disease.
Read More
Treating Early Onset Colorectal Cancer in Young Adults
April 29th 2020In an interview with Targeted Oncology following SOGO 2020, Andrea Cercek, MD, discussed the rising incidence of CRC in young adults in detail. She also advised community oncologists who encounter these patients in their clinics.
Read More
Updated Analysis Confirms Safety of Eryaspase in Advanced Metastatic Pancreatic Cancer
April 22nd 2020"The third independent safety review has once again confirmed the favorable safety profile of our lead product candidate eryaspase, and the trial has now surpassed 75% of the planned target enrollment."
Read More
FDA Grants Two Fast Track Designations to Surufatinib in Pancreatic and Extrapancreatic NETs
April 17th 2020The FDA granted two Fast Track designations to surufatinib for the treatment of both advanced and progressive pancreatic neuroendocrine tumors and extra-pancreatic NETs in patients who are not amenable for surgery, according to a press release from the developer, Chi-Med. The agent was previously granted Orphan Drug Designation by the FDA for this indication.
Read More
Liquid Biopsy Accurately Detects Early-Stage Pancreatic Ductal Adenocarcinoma
April 17th 2020A liquid biopsy test with the ability to screen for a panel of biomarkers rather than just one can reportedly detect pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, in the early stages of disease.
Read More